Zometa for the Management of Tumor-induced Hypercalcemia and Malignant Bone Pain in the Community
Status:
Completed
Trial end date:
2006-09-01
Target enrollment:
Participant gender:
Summary
Treatment in the home and hospice of long-term care facilities, particularly for
non-ambulatory patients, could provide significant advantages for patients and for the
region. The Calgary Health Region has a unique resource in the home parenteral therapy
program (HPTP). With the assistance of HPTP, patients requiring bisphosphonate treatment for
the management of tumor-induced hypercalcemia (TIH) or malignant bone pain (MBP) could be
treated in the community (ie at home). However, the resources required and the costs
associated with community-based (homes, hospices, long-term care facilities) treatment of TIH
and MBP need to be identified and evaluated so as to guide future regional decision making.